These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11009057)

  • 1. Policing the European pharmaceutical market's priorities.
    Garattini S; Bertele' V
    Eur J Clin Pharmacol; 2000 Aug; 56(5):441-3. PubMed ID: 11009057
    [No Abstract]   [Full Text] [Related]  

  • 2. New technology, old struggles plague vaccine developers.
    Phillips L
    Hosp Technol Ser; 1994 Oct; 13(13):3-6. PubMed ID: 10137963
    [No Abstract]   [Full Text] [Related]  

  • 3. The medicine cabinet: what's in it, why, and can we change the contents?
    Croghan TW; Pittman PM
    Health Aff (Millwood); 2004; 23(1):23-33. PubMed ID: 15002625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Standards for commercialization of medications in the European Union].
    Benzi G
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):33-7. PubMed ID: 12497878
    [No Abstract]   [Full Text] [Related]  

  • 5. European researchers up in arms over new clinical trials edict.
    Bosch X
    Nat Med; 2003 Nov; 9(11):1336. PubMed ID: 14595413
    [No Abstract]   [Full Text] [Related]  

  • 6. Maximizing exclusivity for drug products.
    French H
    Nat Rev Drug Discov; 2005 Sep; 4(9):709. PubMed ID: 16178117
    [No Abstract]   [Full Text] [Related]  

  • 7. Europe: a missed opportunity, with dangers and hopes.
    Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540841
    [No Abstract]   [Full Text] [Related]  

  • 8. [The EEC--the domestic market's social dimension].
    Stallknecht K; Lunding K
    Sygeplejersken; 1990 Aug; 90(32):16-7. PubMed ID: 2291173
    [No Abstract]   [Full Text] [Related]  

  • 9. The Transatlantic Trade and Investment Partnership: Trojan horse or positive force for health?
    Faure M; Ward B
    Eur Respir J; 2015 Jul; 46(1):22-5. PubMed ID: 26130778
    [No Abstract]   [Full Text] [Related]  

  • 10. Can a medical need clause help manage the growing costs of prescription drugs in the EU?
    Brooks E; Geyer R
    Health Econ Policy Law; 2016 Apr; 11(2):179-92. PubMed ID: 26333920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Southern states receive pharmaceutical grants to fight HIV/AIDS.
    AIDS Policy Law; 2003 Aug; 18(16):9. PubMed ID: 14626922
    [No Abstract]   [Full Text] [Related]  

  • 12. [The structure of distribution of pharmaceutical products in the countries of the EEC].
    Passerini F
    Boll Chim Farm; 1990 May; 129(5):199-209. PubMed ID: 2083056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of implications of adaptive licensing for pharmaceutical intellectual property and regulatory exclusivity rights in the European Union.
    Meier A; Faulkner SD; Schoonderbeek C; Jong B; Kung J; Brindley D; Barker R
    Clin Pharmacol Ther; 2016 Dec; 100(6):743-753. PubMed ID: 27626890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical telematics and telemedicine: an agenda for research evaluation in Scotland.
    Lewis M; Moir AT
    Health Bull (Edinb); 1995 Mar; 53(2):129-37. PubMed ID: 7737875
    [No Abstract]   [Full Text] [Related]  

  • 16. Health in Europe--policies for progress.
    Ricciardi W
    Lancet; 2013 Mar; 381(9872):1075-6. PubMed ID: 23541051
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategic funding priorities in the pharmaceutical sciences allied to Quality by Design (QbD) and Process Analytical Technology (PAT).
    Aksu B; De Beer T; Folestad S; Ketolainen J; Lindén H; Lopes JA; de Matas M; Oostra W; Rantanen J; Weimer M
    Eur J Pharm Sci; 2012 Sep; 47(2):402-5. PubMed ID: 22749874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International diversification and US regulatory controls in the pharmaceutical industry.
    Goedde AG
    Q Rev Econ Bus; 1982; 22(1):101-10. PubMed ID: 10317195
    [No Abstract]   [Full Text] [Related]  

  • 19. Palliative care activity in the field of oncology in Turkey.
    Ozcelik H; Fadiloglu C; Karabulut B; Uyar M
    J Palliat Care; 2010; 26(4):305-10. PubMed ID: 21268524
    [No Abstract]   [Full Text] [Related]  

  • 20. [The German law on reorganization of the pharmaceutical market (AMNOG): distinction between innovations and pseudoinnovations].
    Doht C
    Internist (Berl); 2013 Oct; 54(10):1274. PubMed ID: 24026791
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.